News | May 24, 2012

Data Suggests Multi-Disciplinary Convergent Ablation Procedure May Restore Persistent AFib to Normal Sinus Rhythm

Physician Presentations at Heart Rhythm 2012 Highlight New 12+ Month Data, with Over 80 percent in Sinus Rhythm

May 24, 2012 -- nContact Inc., a provider of  epicardial ablation devices, announced that new long-term physician data demonstrated promising clinical outcomes for the multidisciplinary Convergent Procedure in the treatment of persistent atrial fibrillation (AF), with more than 80% of patients remaining in sinus rhythm at a minimum of 12 months follow-up. The data was presented by physicians at Heart Rhythm 2012, the Heart Rhythm Society's 33rd Annual Scientific Sessions, May 9-12 in Boston.

Abstract Presentation: "Combined Epicardial and Endocardial Ablation for Atrial Fibrillation: Single Center Experience in 100 Consecutive Patients"

During the oral abstract sessions, a presentation by Kenneth C. Civello, M.D., Our Lady of the Lake Medical Center, Baton Rouge, La., highlighted clinical outcomes from 104 consecutive patients treated with the Convergent Procedure. Of these, 73% suffered with persistent or permanent AF. Results demonstrated that 86% of patients who reached six months follow-up were in sinus rhythm, with 78% in sinus rhythm off anti-arrhythmic drugs (AADs). Of the 40 patients who have reached 12 month follow-up, 81% were in sinus rhythm, with 69% in sinus rhythm off AADs.

"The combined endocardial and epicardial approach enabled by the Convergent Procedure allows physicians to more efficiently achieve complete, transmural lesions across the posterior of the heart, which research demonstrates is key to adequately addressing this challenging condition," said Civello. "We feel this multidisciplinary approach is a viable treatment option for persistent patients and is an essential component of our EP toolbox."

Poster: "Collaboration of Cardiac Surgery and Electrophysiology to Treat Atrial Fibrillation: Convergent Procedure Outcomes from a Single Center"

A poster presented by David M. Gilligan, M.D., Levinson Heart Hospital at CJW Medical Center, Richmond, Va., reviewed data from a prospective registry of the first 39 patients to undergo ablation with the Convergent Procedure at the center, 79% of whom suffered with persistent or longstanding persistent AF. At 12 months post procedure, 96% of patients were in sinus rhythm with nearly 70% in sinus rhythm off AADs.

"We incorporated the Convergent Procedure at our center as a collaboration between surgeons and electrophysiologists and have seen promising clinical outcomes. Our experience suggests this combined approach may offer a viable treatment option for patients with persistent AF by maintaining sinus rhythm after a single ablation procedure," said Gilligan.

Poster: "Clinical Outcomes of a new Epicardial/Endocardial Ablation Procedure (Convergent) for the Treatment of Atrial Fibrillation"

A poster presented by Keith M. Golden, M.D., St. Vincent Hospital, Indianapolis, demonstrated positive outcomes on 60 patients undergoing the Convergent Procedure, considering 88% of patients had persistent or longstanding persistent AF. This was a difficult cohort of patients with enlarged left atria, and an average BMI over 35. At an average follow up of 11 months (333 +/- 156 days), 79% of patients were in sinus rhythm. Notably, this continued to hold true for the 14 patients who reached 18 months follow-up, with 79% remaining in sinus rhythm, all of whom were also off AADs.

The various posters and presentations reaffirmed the ability of the Convergent Procedure to achieve consistent single procedure results across hospital sites. The potential advantage of the Convergent Procedure is that it integrates the best practices of surgeons and electrophysiologists in a single setting, utilizing a minimally invasive, trans-diaphragmatic approach for direct access to the posterior of the left atrium without chest incisions, lung deflation, or cardiac dissections. Developed by physicians and enabled by nContact's epicardial ablation technology, it has been shown to be especially appropriate for AF patients with enlarged atria and persistent or long-standing persistent stages of disease.

nContact's Numeris Coagulation System with VisiTrax and EPi-Sense Coagulation System technology integrates suction, perfusion and radiofrequency energy to ensure consistent cardiac tissue contact and create visible, continuous lesions on the epicardium of a beating heart.

For more information: and

Related Content

New FDA Proposed Rule Alters Informed Consent for Clinical Studies
News | Cardiovascular Clinical Studies | November 19, 2018
The U.S. Food and Drug Administration (FDA) is proposing to add an exception to informed consent requirements for...
A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development. #SCAI, #SCAI2018

A key slide from Elnabawi's presentation, showing cardiac CT plaque evaluations, showing the impact of psoriasis medication on coronary plaques at baseline and one year of treatment. It shows a reversal of vulnerable plaque development.  

Feature | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 – New clinical evidance shows common therapy options for psoriasis (PSO), a chronic inflammatory skin di
Intravenous Drug Use is Causing Rise in Heart Valve Infections, Healthcare Costs. #SCAI, #SCAI2018
News | Cardiovascular Clinical Studies | May 14, 2018
May 14, 2018 — The opioid drug epidemic is impacting cardiology, with a new study finding the number of patients hosp
Patient Enrollment Completed in U.S. IDE Study of THERMOCOOL SMARTTOUCH SF Catheter
News | Cardiovascular Clinical Studies | March 15, 2018
March 15, 2018 –  Johnson & Johnson Medical Devices Companies announced today that Biosense Webster, Inc., who wo
Lexington Begins HeartSentry Clinical Trial
News | Cardiovascular Clinical Studies | February 20, 2018
February 20, 2018 – Lexington Biosciences, Inc., a development-stage medical device company, announced the commenceme
Endologix Completes Patient Enrollment in the ELEVATE IDE Clinical Study
News | Cardiovascular Clinical Studies | February 06, 2018
February 6, 2018 – Endologix, a developer and marketer of treatments for aortic disorders, announced the completion o
12-Month Results from Veryan Medical's MIMICS-2 IDE Study Presented at LINC
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 – Thomas Zeller (Bad Krozingen, Germany) presented the 12-month results from Veryan Medical’s MIMICS
LimFlow Completes U.S. Feasibility Study Enrollment, Receives FDA Device Status
News | Cardiovascular Clinical Studies | February 01, 2018
February 1, 2018 –  LimFlow SA, developer of minimally-inv
ESC 2017 late breaking trial hot line study presentations.
News | Cardiovascular Clinical Studies | September 12, 2017
September 12, 2017 – The European Society of Cardiology (ESC) Congress 2017 includes several Hot Line Late-breaking C
U.K., NHS studies, weekend effect, hospital admission, atrial fibrillation, heart failure
News | Cardiovascular Clinical Studies | June 28, 2016
New research shows patients admitted to National Health Service (NHS) hospitals in the United Kingdom for atrial...
Overlay Init